Tobias Nordström

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Tobias Nordström är verksam som urolog och självständig forskare. Han är
ansvarig för kliniska studier med målet att förbättra diagnostik och
behandling av prostatacancer.
Jag är kliniskt verksam vid Kirurg- och Urologkliniken, Danderyds Sjukhus
och behandlar män med prostatacancer och andra urologiska diagnoser. Jag
är ansvarig (PI) för STHLM3MR-projektet där man studerar om en
kombination av blodprov, bild-diagnostik med MR-undersökningar och så
kallade riktad vävnadsprovtagning kan ersätta traditionell utredning för
prostatacancer. Mitt vetenskapliga arbete inkluderar också flera projekt
där existerande studiekohorter används för att studera hur klinisk praxis
bedrivs och kan förbättras med bland annat nya biomarkörer och verktyg
för riskbedömning.
* 2024 Scientific Congress Office, European Association of Urology
* 2024 Best scientific paper award, Swedish Urological Society (SUF)
* 2022 Prostate Cancer Research Award, European Association of Urology
* 2021 Best Abstract Oncology, European Association of Urology annual congress
* 2017 European Meeting on Urinary Cancers (EMUC) - Best poster award
* 2017 Astellas Cutting Edge Award
* 2016 European Association of Urology (EAU) Annual Meeting - Best poster
award
* 2014 StratCan International Postdoc award
* 2011 StratCan Ph.D. award
* 2011 Forskar-ST
* 2021- Överläkare Danderyds Sjukhus
* 2016 Postdoc (Inst för Medicinsk epidemiologi och biostatistik, KI)
* 2015 Specialistläkare Urologi (Danderyds Sjukhus AB)
* 2015 Fellow of the European Board of Urology (FEBU)
* 2015 Postdoc (University of California, San Francisco)
* 2015 Medicine Doktor (Inst Kliniska vetenskaper vid Danderyds Sjukhus,
KI)
* 2013 Specialistläkare Kirurgi (Danderyds Sjukhus AB)

Forskningsbeskrivning

Avhandling: Predicting Prostate Cancer - on the use of biomarkers in Prostate
Cancer Diagnostics [1]
[1] https://openarchive.ki.se/xmlui/handle/10616/42331

Artiklar

Journal article: NATURE REVIEWS UROLOGY. 2024;:1-4
Tomorrow's patient management: LLMs empowered by external tools
Szolnoky K; Nordstrom T; Eklund M
Article: EUROPEAN UROLOGY ONCOLOGY. 2024;:S2588-9311(24)00244-X
Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging-guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Discacciati A; Abbadi A; Clements MS; Annerstedt M; Carlsson S; Grönberg H; Jäderling F; Eklund M; Nordström T
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(32):3806-3816
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial
Vigneswaran HT; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern MR; Moreira DM; Eggener S; Yonover P; Chow AK; Watts K; Liss MA; Thoreson GR; Abreu AL; Sonn GA; Palsdottir T; Plym A; Wiklund F; Gronberg H; Murphy AB
Article: EUROPEAN UROLOGY ONCOLOGY. 2024;:S2588-9311(24)00229-3
Diagnostic Effects of Omitting Systematic Biopsies in Prostate Cancer Screening.
Chandra Engel J; Eklund M; Jäderling F; Palsdottir T; Falagario U; Discacciati A; Nordström T
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2024;116(9):1459-1465
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists
Bjornebo L; Razdan S; Discacciati A; Palsdottir T; Aly M; Nordstrom T; Eklund M; Lundon D; Gronberg H; Tewari A; Wiklund P; Kyprianou N; Lantz A
Article: BMC UROLOGY. 2024;24(1):168
Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
Jaderling F; Bergman M; Engel JC; Mortezavi A; Picker W; Haug ES; Eklund M; Nordstrom T
Article: JOURNAL OF MAGNETIC RESONANCE IMAGING. 2024;60(2):458-468
Prostate Age Gap: An MRI Surrogate Marker of Aging for Prostate Cancer Detection
Fernandez-Quilez A; Nordstrom T; Jaederling F; Kjosavik SR; Eklund M
Article: BJU INTERNATIONAL. 2024;133(6):680-689
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
Loffeler S; Bertilsson H; Mueller C; Aas K; Haugnes HS; Aksnessaether B; Pesonen M; Thon K; Tandstad T; Murtola T; Poulsen MH; Nordstrom T; Vigmostad MN; Ottosson F; Holmsten K; Christiansen O; Slaaen M; Haug ES; Storas AH; Asphaug L; Rannikko A; Brasso K
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e623
PD29-12 THE IMPACT OF THE TIME ELAPSED BETWEEN PRIMARY TREATMENT AND BCR ON CANCER SPECIFIC MORTALITY IN PATIENTS WHO EXPERIENCED BCR AFTER PRIMARY TREATMENT
Pellegrino F; Falagario UG; Abbadi A; Björnebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e314
MP19-10 ADDITIONAL VALUE OF MRI IN PATIENTS WITH PSA >10 NG/ML AND/OR POSITIVE DRE: IS MRI ALWAYS NEEDED?
Guzzi F; Falagario U; Lantz A; Carmignani L; Montanari E; Bove P; Gontero P; Porpiglia F; Sciarra A; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Ludovico G; Ricapito A; Busetto GM; Ficarra V; Nordstrom T; Bostrom P; De Cobelli O; Cormio L; Carrieri G
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e1213
PD57-12 PSA RESPONSE AFTER RADIOTHERAPY. IS THERE A DEFINITION OF PSA PERSISTENCE AFTER RT?
Falagario UG; Pellegrino F; Abbadi A; Björnebo L; Valdman A; Carrieri GG; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e788
MP49-13 INTERCENTER VARIABILITY IN THE ACCURACY OF RISK CALCULATORS BASED ON MRI PARAMETERS: EXTENSIVE EXTERNAL VALIDATION OF 7 CONTEMPORARY RISK CALCULATORS
Tocci E; Falagario U; Lantz A; Jambor I; Busetto GM; Bettocchi C; Cormio L; Nordstrom T; Schips L; Gontero P; Carmignani L; Bove P; Montanari E; Trombetta C; Simone G; Ficarra V; Ludovico G; Mirone V; Antonelli A; Porpiglia F; Bassi P; Bostrom PJ; De Cobelli O; Carrieri G
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e1197
MP74-12 IMPACT OF MAGNETIC RESONANCE IMAGING SCAN AND IMAGE ACQUISITION PROTOCOL IN DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER AT BIOPSY: RESULTS FROM THE PROMOD WORKING GROUP
Fanelli A; Finati M; Falagario UG; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G
Article: JAMA NETWORK OPEN. 2024;7(4):e247131
Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial
Bjornebo L; Discacciati A; Falagario U; Vigneswaran HT; Jaderling F; Gronberg H; Eklund M; Nordstrom T; Lantz A
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;62:61-67
Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer
Arvendell M; Bjornebo L; Eklund M; Falagario UG; Engel JC; Akre O; Gronberg H; Nordstrom T; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1692-s1693
Stockholm3 validation in a multi-Ethnic cohort for ProsTAte cancer (SEPTA) detection: A multicentered, prospective trial
Vigneswaran HT; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern M; Moreira D; Eggener S; Yonover P; Chow A; Watts K; Liss M; Thoreson G; Abreu AL; Sonn GA; Palsdottir T; Plym A; Wiklund F; Gronberg H; Murphy AB
Journal article: EUROPEAN UROLOGY. 2024;85:s1598
Can we reduce unnecessary prostate biopsies in patients with PI-RADS 3 lesions? Role of PSA density and the Stockholm 3 test
Abbadi A; Eklund M; Lantz A; Discacciati A; Engel CJ; Bjornebo L; Falagario UG; Gronberg H; Nordstrom T
Journal article: EUROPEAN UROLOGY. 2024;85:s1611
Multiplex blood-test and Magnetic Resonance Imaging (MRI) for prostate cancer screening: Results from the 2nd screening round in the STHLM3-MRI trial
Discacciati A; Abbadi A; Chandra J; Annerstedt M; Glaessgen A; Carlsson S; Jaderling F; Gronberg H; Eklund M; Nordstrom T
Journal article: EUROPEAN UROLOGY. 2024;85:s1674-s1675
Stockholm3 to predict post-operative risk and biochemical recurrence after radical prostatectomy: Evidence from the STHLM3 trial
Vigneswaran HT; Palsdottir T; Gronberg H; Nordstrom T; Egevad L; Eklund M
Journal article: EUROPEAN UROLOGY. 2024;85:s411-s412
Prostate cancer testing in Stockholm; comparing compliance to follow up of men with elevated PSA vs elevated Stockholm3 in clinical practice between 2018 to 2020
Palsdottir T; Vigneswaran H; Gronberg H; Nordstrom T
Article: EUROPEAN UROLOGY. 2024;85(3):207-214
Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men
Bratt O; Godtman RA; Jiborn T; Wallstrom J; Akre O; Carlsson S; Nordstrom T; Thimansson E; Alterbeck M; Zackrisson S; Hugosson J; Bjartell A; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1534-s1535
The impact of the time elapsed between primary treatment and BCR on cancer specific mortality in patients who experienced BCR after primary treatment
Pellegrino F; Falagario UG; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Journal article: EUROPEAN UROLOGY. 2024;85:s1602-s1603
Organised prostate cancer testing in Sweden - results from the first three years of inviting 50-year-old men
Godtman AR; Jiborn T; Wallstrom J; Akre O; Carlsson S; Nordstrom T; Thimansson E; Alterbeck M; Zackrisson S; Hugosson J; Bjartell A; Lantz A; Bratt O
Journal article: EUROPEAN UROLOGY. 2024;85:s348
Pre-diagnostic prostate-specific antigen testing and clinical characteristics in men deceased from prostate cancer
Arvendell M; Bjornebo L; Eklund M; Falagario GU; Akre O; Gronberg H; Nordstrom T; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1402-s1403
PSA response after radiotherapy. Is there a definition of PSA persistence after RT?
Falagario UG; Pellegrino F; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s448-s449
Impact of magnetic resonance imaging scan and image acquisition protocol in detecting clinically significant prostate cancer at biopsy: Results from the PROMOD working group
Fanelli A; Finati M; Falagario UG; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G
Journal article: EUROPEAN UROLOGY. 2024;85:s1672
Intercenter variability in the accuracy of risk calculators based on MRI parameters: Extensive external validation of 7 contemporary risk calculators
Tocci E; Falagario U; Lantz A; Carmignani L; Montanari E; Bove P; Gontero P; Porpiglia F; Sciarra A; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Ludovico G; Ricapito A; Busetto G; Ficarra V; Bostrom P; De Cobelli O; Nordstrom T; Cormio L; Carrieri G
Article: JAMA NETWORK OPEN. 2024;7(2):e2354577
Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial
Nordstrom T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Groenberg H; Jaderling F; Eklund M; Discacciati A
Article: PLOS ONE. 2024;19(8):e0308254
Spatio-temporal variation in prostate cancer testing in Stockholm: A population-based study
Rai B; Nordstrom T; Lantz A; Lund RL; Kuja-Halkola R; Rado M; Oberg S; Hao S; Du X; Clements M
Article: ANNALS OF MEDICINE. 2023;55(1):1123-1133
Association between participation in the Northern Finland Birth Cohorts and cardiometabolic disorders
Kerkela M; Gissler M; Nordstrom T; Ukkola O; Veijola J
Article: NATURE GENETICS. 2023;55(12):2065-2074
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Wang A; Shen J; Rodriguez AA; Saunders EJ; Chen F; Janivara R; Darst BF; Sheng X; Xu Y; Chou AJ; Benlloch S; Dadaev T; Brook MN; Plym A; Sahimi A; Hoffman TJ; Takahashi A; Matsuda K; Momozawa Y; Fujita M; Laisk T; Figueredo J; Muir K; Ito S; Liu X; Uchio Y; Kubo M; Kamatani Y; Lophatananon A; Wan P; Andrews C; Lori A; Choudhury PP; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Giles GG; Southey MC; MacInnis RJ; Cybulski C; Wokolorczyk D; Lubinski J; Rentsch CT; Cho K; Mcmahon BH; Neal DE; Donovan JL; Hamdy FC; Martin RM; Nordestgaard BG; Nielsen SF; Weischer M; Bojesen SE; Roder A; Stroomberg HV; Batra J; Chambers S; Horvath L; Clements JA; Tilly W; Risbridger GP; Gronberg H; Aly M; Szulkin R; Eklund M; Nordstrom T; Pashayan N; Dunning AM; Ghoussaini M; Travis RC; Key TJ; Riboli E; Park JY; Sellers TA; Lin H-Y; Albanes D; Weinstein S; Cook MB; Mucci LA; Giovannucci E; Lindstrom S; Kraft P; Hunter DJ; Penney KL; Turman C; Tangen CM; Goodman PJ; Thompson IMJ; Hamilton RJ; Fleshner NE; Finelli A; Parent M-E; Stanford JL; Ostrander EA; Koutros S; Freeman LEB; Stampfer M; Wolk A; Hakansson N; Andriole GL; Hoover RN; Machiela MJ; Sorensen KD; Borre M; Blot WJ; Zheng W; Yeboah ED; Mensah JE; Lu Y-J; Zhang H-W; Feng N; Mao X; Wu Y; Zhao S-C; Sun Z; Thibodeau SN; McDonnell SK; Schaid DJ; West CML; Barnett G; Maier C; Schnoeller T; Luedeke M; Kibel AS; Drake BF; Cussenot O; Cancel-Tassin G; Menegaux F; Truong T; Koudou YA; John EM; Grindedal EM; Maehle L; Khaw K-T; Ingles SA; Stern MC; Vega A; Gomez-Caamano A; Fachal L; Rosenstein BS; Kerns SL; Ostrer H; Teixeira MR; Paulo P; Brandao A; Watya S; Lubwama A; Bensen JT; Butler EN; Mohler JL; Taylor JA; Kogevinas M; Dierssen-Sotos T; Castano-Vinyals G; Cannon-Albright L; Teerlink CC; Huff CD; Pilie P; Yu Y; Bohlender RJ; Gu J; Strom SS; Multigner L; Blanchet P; Brureau L; Kaneva R; Slavov C; Mitev V; Leach RJ; Brenner H; Chen X; Holleczek B; Schoettker B; Klein EA; Hsing AW; Kittles RA; Murphy AB; Logothetis CJ; Kim J; Neuhausen SL; Steele L; Ding YC; Isaacs WB; Nemesure B; Hennis AJM; Carpten J; Pandha H; Michael A; De Ruyck K; De Meerleer G; Ost P; Xu J; Razack A; Lim J; Teo S-H; Newcomb LF; Lin DW; Fowke JH; Neslund-Dudas CM; Rybicki BA; Gamulin M; Lessel D; Kulis T; Usmani N; Abraham A; Singhal S; Parliament M; Claessens F; Joniau S; Van den Broeck T; Gago-Dominguez M; Castelao JE; Martinez ME; Larkin S; Townsend PA; Aukim-Hastie C; Bush WS; Aldrich MC; Crawford DC; Srivastava S; Cullen J; Petrovics G; Casey G; Wang Y; Tettey Y; Lachance J; Tang W; Biritwum RB; Adjei AA; Tay E; Truelove A; Niwa S; Yamoah K; Govindasami K; Chokkalingam AP; Keaton JM; Hellwege JN; Clark PE; Jalloh M; Gueye SM; Niang L; Ogunbiyi O; Shittu O; Amodu O; Adebiyi AO; Aisuodionoe-Shadrach OI; Ajibola HO; Jamda MA; Oluwole OP; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Diop H; Gundell SM; Roobol MJ; Jenster G; van Schaik RHN; Hu JJ; Sanderson M; Kachuri L; Varma R; McKean-Cowdin R; Torres M; Preuss MH; Loos RJF; Zawistowski M; Zollner S; Lu Z; Van Den Eeden SK; Easton DF; Ambs S; Edwards TL; Magi R; Rebbeck TR; Fritsche L; Chanock SJ; Berndt SI; Wiklund F; Nakagawa H; Witte JS; Gaziano JM; Justice AC; Mancuso N; Terao C; Eeles RA; Kote-Jarai Z; Madduri RK; Conti DV; Haiman CA
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2023;57:s104-s105
P069 PSA persistence after prostatectomy – prognosis and the effect of adjuvant radiotherapy
Möller A; Nordström T; Eklund M; Akre O; Egevad L; Aly M
Article: WORLD JOURNAL OF UROLOGY. 2023;41(11):2967-2974
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
Falagario UG; Lantz A; Jambor I; Busetto GM; Bettocchi C; Finati M; Ricapito A; Luzzago S; Ferro M; Musi G; Totaro A; Racioppi M; Carbonara U; Checcucci E; Manfredi M; D'Aietti D; Porcaro AB; Nordstrom T; Bjornebo L; Oderda M; Soria F; Taimen P; Aronen HJ; Perez IM; Ettala O; Marchioni M; Simone G; Ferriero M; Brassetti A; Napolitano L; Carmignani L; Signorini C; Conti A; Ludovico G; Scarcia M; Trombetta C; Claps F; Traunero F; Montanari E; Boeri L; Maggi M; Del Giudice F; Bove P; Forte V; Ficarra V; Rossanese M; Mucciardi G; Pagliarulo V; Tafuri A; Mirone V; Schips L; Antonelli A; Gontero P; Cormio L; Sciarra A; Porpiglia F; Bassi P; Ditonno P; Bostrom PJ; Messina E; Panebianco V; De Cobelli O; Carrieri G
Journal article: SYSTEMATIC REVIEWS. 2023;12(1):170
Increasing the transparency of systematic reviews: presenting a generalized registration form.
van den Akker OR; Peters G-JY; Bakker CJ; Carlsson R; Coles NA; Corker KS; Feldman G; Moreau D; Nordström T; Pickering JS; Riegelman A; Topor MK; van Veggel N; Yeung SK; Call M; Mellor DT; Pfeiffer N
Article: JAMA NETWORK OPEN. 2023;6(9):e2332900
Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy
Falagario UG; Abbadi A; Remmers S; Bjornebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Article: LAKARTIDNINGEN. 2023;120:23077
[Improved prostate cancer diagnostics with a structured pathway including »Stockholm 3« test, MRI and targeted perineal biopsies].
Söderbäck H; Jäderling F; Wimmerkranz F; Andersson J; Bergman M; Nordström T; Grönberg H
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2023;51:89-94
Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer
Lantz A; Nordlund P; Falagario U; Joderling F; Ozbek O; Clements M; Discacciati A; Gronberg H; Eklund M; Stricker P; Emberton M; Aly M; Nordstrom T
Article: EUROPEAN UROLOGY FOCUS. 2023;9(3):455-462
External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort
Palsdottir T; Gronberg H; Hilmisson A; Eklund M; Nordstrom T; Vigneswaran HT
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e997
PD38-11 THE STOCKHOLM3 PROSTATE CANCER SCREENING TRIAL (STHLM3): AN INTERIM ANALYSIS OF MORTALITY RESULTS AFTER 6.5 YEARS OF FOLLOW-UP
Micoli C; Crippa A; Discacciati A; Palsdottir T; Vigneswaran H; Aly M; Adolfsson J; Lindberg J; Wiklund P; Thompson J; Brandberg Y; Clements M; Egevad L; Grönberg H; Nordström T; Eklund M
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e1048
PD39-08 INTER-CENTER VARIABILITY IN POSITIVE PREDICTIVE VALUES OF PIRADS SCORE IN PATIENTS UNDERGOING PROSTATE BIOPSY: RESULTS FROM THE PROMOD STUDY GROUP
Falagario U; Finati M; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e419
PD15-04 PREDICTION OF PROSTATE CANCER SPECIFIC MORTALITY IN MEN UNDERGOING RADIOTHERAPY WITH OR WITHOUT HORMONAL TREATMENT, RISK STRATIFICATION BASED ON CLINICAL CHARACTERISTICS AND PSA TREATMENT RESPONSE
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e214
MP17-06 VALIDATION OF EAU RISK GROUPS FOR BIOCHEMICAL RECURRENCE AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY FOR PREDICTION OF PROSTATE CANCER MORTALITY
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Journal article: EUROPEAN UROLOGY. 2023;83:s1266-s1267
The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up
Micoli C; Crippa A; Discacciati A; Vigneswaran H; Palsdottir T; Clements M; Aly M; Adolfsson J; Fredrik W; Wiklund P; James T; Lindberg J; Gronberg H; Egevad L; Nordstrom T; Eklund M
Journal article: EUROPEAN UROLOGY. 2023;83:s1268
Repeat prostate cancer screening using prostate-specific antigen, a multiplex bloodtest and magnetic resonance imaging: 2nd screening round outcomes of STHLM3-MRI
Nordstrom T; Discacciati A; Annerstedt M; Mannsikka K; Glaessgen A; Carlsson S; Jaderling F; Gronberg H; Eklund M
Journal article: EUROPEAN UROLOGY. 2023;83:s1613-s1614
Prediction of prostate cancer specific mortality in men undergoing radiotherapy with or without hormonal treatment, risk stratification based on clinical characteristics and PSA treatment response
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2023;83:s87-s88
A0059 Development and multicenter validation of the PROMOD Likert scale including PIRADS score and PSA density for risk stratification of patients with a Positive MRI
Falagario U; Finati M; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G; Group PW
Journal article: EUROPEAN UROLOGY. 2023;83:s1293-s1294
External validation of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and comparison to Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort
Palsdottir T; Gronberg H; Hilmisson A; Eklund M; Nordstrom T; Vigneswaran H
Journal article: EUROPEAN UROLOGY. 2023;83:s1390-s1391
Inter-center variability in positive predictive values of PIRADS score in patients undergoing prostate biopsy: Results from the PROMOD study group
Falagario U; Finati M; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di TP; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G
Journal article: EUROPEAN UROLOGY. 2023;83:s379-s380
A0266 Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Article: JAMA ONCOLOGY. 2022;9(1):88-94
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study
Hao S; Discacciati A; Eklund M; Heintz E; Ostensson E; Elfstrom KM; Clements MS; Nordstrom T
Article: EUROPEAN UROLOGY. 2022;82(5):559-568
Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging- detected Prostate Imaging Reporting and Data System/Likert >3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score
Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Shah TT; Verhoeff JJC; Taimen P; Aronen HJ; Knaapila J; Perez IM; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug ES; Nordstrom T; Tanaka MB; Reddy D; Bass E; van Rossum PSN; Wong K; Tam H; Winkler M; Gordon S; Qazi H; Bostrom PJ; Jambor I; Ahmed HU
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;44:69-75
Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
Andersson J; Palsdottir T; Lantz A; Aly M; Gronberg H; Egevad L; Eklund M; Nordstrom T
Article: EUROPEAN UROLOGY. 2022;82(1):12-19
Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study
Hao S; Heintz E; Ostensson E; Discacciati A; Jaderling F; Gronberg H; Eklund M; Nordstrom T; Clements MS
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;41:1-7
External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
Engel JC; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Gronberg H; Eklund M; Nordstrom T
Article: JAMA ONCOLOGY. 2022;8(7):1019-1026
Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;41:45-54
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordstrom T; Briganti A; Bostrom PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e991
MP58-03 PROSTATE CANCER SCREENING - A NOVEL RISK PREDICTION TOOL WITH STANDARD BIOPSIES VS. PSA WITH MRI-TARGETED BIOPSIES
Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e41
PD03-02 LONG-TERM EFFECTS OF 5Α-REDUCTASE INHIBITORS ON PROSTATE CANCER MORTALITY - A LARGE POPULATION-BASED PROSPECTIVE STUDY
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e336
PD17-01 DERIVATION AND EXTERNAL VALIDATION OF A RAPID RISK SCORE FOR PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH AN MRI VISIBLE LESION: A MULTINATIONAL COHORT STUDY
Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Verhoeff JJC; Carrieri G; Cormio L; Taimen P; Aronen HJ; Knaapila J; Perez IM; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug E; Nordström T; Tanaka MB; Hosking-Jervis F; Reddy D; Bass E; van Rossum PSN; Joshi S; Pegers E; Wong K; Tam H; Hrouda D; McCraken S; Winkler M; Gordon S; Qazi H; Boström PJ; Jambor I; Ahmed HU
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e689
PD41-02 DIAGNOSIS OF PROSTATE CANCER IN MEN TREATED WITH 5-ALPHA-REDUCATES INHIBITORS WITH MULTIPARAMETRIC MRI: RESULTS OF A MULTICENTER INTERNATIONAL COLLABORATION
Falagario U; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Ferro M; Bostrom P; Nordström T; de Cobelli O; Cormio L; Carrieri G
Journal article: RADIOTHERAPY AND ONCOLOGY. 2022;170:s360-s361
PD-0416 Derivation and external validation of a RAPID Risk score for predicting significant prostate cancer
Peters M; Eldred-Evans D; Connor MJ; Tanaka MB; Bhola-Stewart H; Shah TT; Ahmad S; Noureldin M; Wong K; Tam H; Hrouda D; Winkler M; van Rossum P; Kurver P; Gordon S; Qazi H; Ahmed HU; Falagario UG; Jambor I; Briganti A; Nordström T; Carrieri G; Powell L; Joshi S; Pegers E
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2022;38:32-39
A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
Walden M; Aldrimer M; Lagerlof JH; Eklund M; Gronberg H; Nordstrom T; Palsdottir T
Journal article: EUROPEAN UROLOGY. 2022;81:s561-s562
A0362 Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY. 2022;81:s554-s555
A0358 Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies
Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Journal article: EUROPEAN UROLOGY. 2022;81:s1117-s1118
A0754 Diagnosis of prostate cancer in men treated with 5-alpha-reducates inhibitors with multi-parametric MRI: Results of a multicenter international collaboration
Falagario UG; Lantz A; Jambor I; Busetto GM; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Bostrom P; Porpiglia F; Nordström T; De Cobelli O; Cormio L; Carrieri G; Ferro M; Group PS
Article: LAKARTIDNINGEN. 2022;119:21207
Läge för en ny bedömning av screening för prostatacancer.
Nordström T; Eklund M
Article: EUROPEAN UROLOGY ONCOLOGY. 2021;4(6):971-979
Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordstrom T; Tewari A; Briganti A; Bostrom PJ; Carrieri G
Article: VALUE IN HEALTH. 2021;24(12):1763-1772
Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study
Hao S; Karlsson A; Heintz E; Elfstrom KM; Nordstrom T; Clements M
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;33:s216-s217
P011 External validation of the Rotterdam Prostate Cancer Risk Calculator and the Prostate Biopsy Collaborative Group Risk Calculator in a Swedish population-based screening cohort
Engel JC; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2021;385(10):908-920
MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Eklund M; Jaderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Groenberg H; Nordstroem T
Article: THE LANCET ONCOLOGY. 2021;22(9):1240-1249
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
Nordstrom T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jaderling F; Eklund M; Gronberg H
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2021;55(4):299-306
Real world treatment utilization patterns in patients with castration-resistant prostate cancer
Vigneswaran HT; Warnqvist A; Andersson TML; Leval A; Eklund M; Nordstrom T; Eloranta S; Schain F; Dearden L; Liwing J; Mehra M; Nair S; Pettersson A; Akre O; Aly M
Article: WORLD JOURNAL OF UROLOGY. 2021;39(6):1797-1804
Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer
Bjornebo L; Olsson H; Nordstrom T; Jaderling F; Gronberg H; Eklund M; Lantz A
Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2021;24(2):457-464
Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test
Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Loffeler S; Gronberg H; Eklund M; Nordstrom T
Journal article: EUROPEAN UROLOGY. 2021;79:s1429
P1014 Prostate cancer screening using prostate-specific antigen, a multiplex blood-test, magnetic resonance imaging and targeted prostate biopsies: The STHLM3MRI trial
Nordström T; Discacciati A; Bergman M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H
Journal article: EUROPEAN UROLOGY. 2021;79:s1430
P1015 MRI-targeted or systematic biopsies in prostate cancer screening: The STHLM3MRI trial
Eklund M; Jäderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Grönberg H; Nordström T
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2021;113(5):632-640
Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS)
Olsson H; Nordstrom T; Jaderling F; Egevad L; Vigneswaran HT; Annerstedt M; Gronberg H; Eklund M; Lantz A
Article: EUROPEAN UROLOGY FOCUS. 2021;7(3):546-553
Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators
Mortezavi A; Palsdottir T; Eklund M; Chellappa V; Murugan SK; Saba K; Ankerst DP; Haug ES; Nordstrom T; Tilki D
Article: WORLD JOURNAL OF UROLOGY. 2021;39(4):1153-1159
Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies
Lantz A; Haug ES; Picker W; Crippa A; Jaderling F; Mortezavi A; Nordstrom T
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2021;24:11-16
Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
Nordstrom T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Gronberg H
Article: PLOS ONE. 2021;16(2):e0246674
The cost-effectiveness of prostate cancer screening using the Stockholm3 test
Karlsson AA; Hao S; Jauhiainen A; Elfstrom KM; Egevad L; Nordstrom T; Heintz E; Clements MS
Article: NATURE GENETICS. 2021;53(1):65-75
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Conti DV; Darst BF; Moss LC; Saunders EJ; Sheng X; Chou A; Schumacher FR; Al Olama AA; Benlloch S; Dadaev T; Brook MN; Sahimi A; Hoffmann TJ; Takahashi A; Matsuda K; Momozawa Y; Fujita M; Muir K; Lophatananon A; Wan P; Le Marchand L; Wilkens LR; Stevens VL; Gapstur SM; Carter BD; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Giles GG; Southey MC; MacInnis RJ; Cybulski C; Wokolorczyk D; Lubinski J; Neal DE; Donovan JL; Hamdy FC; Martin RM; Nordestgaard BG; Nielsen SF; Weischer M; Bojesen SE; Roder MA; Iversen P; Batra J; Chambers S; Moya L; Horvath L; Clements JA; Tilley W; Risbridger GP; Gronberg H; Aly M; Szulkin R; Eklund M; Nordstrom T; Pashayan N; Dunning AM; Ghoussaini M; Travis RC; Key TJ; Riboli E; Park JY; Sellers TA; Lin H-Y; Albanes D; Weinstein SJ; Mucci LA; Giovannucci E; Lindstrom S; Kraft P; Hunter DJ; Penney KL; Turman C; Tangen CM; Goodman PJ; Thompson IMJ; Hamilton RJ; Fleshner NE; Finelli A; Parent M-E; Stanford JL; Ostrander EA; Geybels MS; Koutros S; Freeman LEB; Stampfer M; Wolk A; Hakansson N; Andriole GL; Hoover RN; Machiela MJ; Sorensen KD; Borre M; Blot WJ; Zheng W; Yeboah ED; Mensah JE; Lu Y-J; Zhang H-W; Feng N; Mao X; Wu Y; Zhao S-C; Sun Z; Thibodeau SN; McDonnell SK; Schaid DJ; West CML; Burnet N; Barnett G; Maier C; Schnoeller T; Luedeke M; Kibel AS; Drake BF; Cussenot O; Cancel-Tassin G; Menegaux F; Truong T; Koudou YA; John EM; Grindedal EM; Maehle L; Khaw K-T; Ingles SA; Stern MC; Vega A; Gomez-Caamano A; Fachal L; Rosenstein BS; Kerns SL; Ostrer H; Teixeira MR; Paulo P; Brandao A; Watya S; Lubwama A; Bensen JT; Fontham ETH; Mohler J; Taylor JA; Kogevinas M; Llorca J; Castano-Vinyals G; Cannon-Albright L; Teerlink CC; Huff CD; Strom SS; Multigner L; Blanchet P; Brureau L; Kaneva R; Slavov C; Mitev V; Leach RJ; Weaver B; Brenner H; Cuk K; Holleczek B; Saum K-U; Klein EA; Hsing AW; Kittles RA; Murphy AB; Logothetis CJ; Kim J; Neuhausen SL; Steele L; Ding YC; Isaacs WB; Nemesure B; Hennis AJM; Carpten J; Pandha H; Michael A; De Ruyck K; De Meerleer G; Ost P; Xu J; Razack A; Lim J; Teo S-H; Newcomb LF; Lin DW; Fowke JH; Neslund-Dudas C; Rybicki BA; Gamulin M; Lessel D; Kulis T; Usmani N; Singhal S; Parliament M; Claessens F; Joniau S; Van den Broeck T; Gago-Dominguez M; Castelao JE; Martinez ME; Larkin S; Townsend PA; Aukim-Hastie C; Bush WS; Aldrich MC; Crawford DC; Srivastava S; Cullen JC; Petrovics G; Casey G; Roobol MJ; Jenster G; van Schaik RHN; Hu JJ; Sanderson M; Varma R; McKean-Cowdin R; Torres M; Mancuso N; Berndt SI; Van den Eeden SK; Easton DF; Chanock SJ; Cook MB; Wiklund F; Nakagawa H; Witte JS; Eeles RA; Kote-Jarai Z; Haiman CA
Article: EUROPEAN UROLOGY ONCOLOGY. 2020;3(5):640-647
Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer
Olsson H; Nordstrom T; Clements M; Gronberg H; Lantz AW; Eklund M
Article: JOURNAL OF CLINICAL PATHOLOGY. 2020;73(10):630-635
Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy
Strom P; Nordstrom T; Delahunt B; Samaratunga H; Gronberg H; Egevad L; Eklund M
Article: SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE. 2020;38(3):315-322
Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience
Viste E; Vinje CA; Lid TG; Skeie S; Evjen-Olsen O; Nordstrom T; Thorsen O; Gilje B; Janssen EAM; Kjosavik SR
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2020;19:e519-e520
305 Discrimination and calibration of the Stockholm3 model with MRI-targeted biopsies
Vigneswaran HT; Olsson H; Haug ES; Grönberg H; Eklund M; Nordström T
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2020;19:e182
58 Adding random systematic biopsies to MRI-fusion targeted prostate biopsy procedures: Always, in selected cases, or never?
Bergman MCA; Mortezawi A; Picker W; Aly M; Jäderling F; Haug E; Eklund M; Nordström T
Article: BMC HEALTH SERVICES RESEARCH. 2020;20(1):448
The economic burden of prostate cancer - a Swedish prevalence-based register study
Hao S; Ostensson E; Eklund M; Gronberg H; Nordstrom T; Heintz E; Clements M
Journal article: INVESTIGATIVE UROLOGY. 2020;203:e1100
PD53-09 DISCRIMINATION AND CALIBRATION OF THE STOCKHOLM3 MODEL WITH MRI-TARGETED BIOPSIES
Vigneswaran* H; Olsson H; Haug ES; Grönberg H; Eklund M; Nordström T
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2020;54(2):115-121
Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden
Aly M; Leval A; Schain F; Liwing J; Lawson J; Vago E; Nordstrom T; Andersson TM-L; Sjoland E; Wang C; Eloranta S; Akre O
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6_suppl):tps379
Incorporating mpMRI and biomarkers in active surveillance protocols: The prospective Stockholm3 Active Surveillance trial (STHLM3AS).
Lantz A; Olsson H; Nordström T; Jäderling F; Egevad L; Annerstedt M; Gronberg H; Eklund M
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6_suppl):tps378
MRI-targeted biopsies in prostate cancer screening and the value of its combination with blood-based risk-prediction: The randomized, diagnostic study STHLM3MRI.
Nordström T; Discacciati A; Jäderling F; Karlsson SG; Aly M; Gronberg H; Eklund M
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2020;54(1):1-6
Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml
Engel JC; Palsdottir T; Aly M; Egevad L; Gronberg H; Eklund M; Nordstrom T
Article: JAMA NETWORK OPEN. 2019;2(11):e1914689
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results
Beckmann K; Crawley D; Nordstrom T; Aly M; Olsson H; Lantz A; Abd Jalal NB; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
Article: EUROPEAN UROLOGY ONCOLOGY. 2019;2(5):490-496
A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging
Palsdottir T; Nordstrom T; Aly M; Jaderling F; Clements M; Gronberg H; Eklund M
Article: EUROPEAN UROLOGY FOCUS. 2019;5(5):842-848
Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study
Aly M; Clements M; Weibull CE; Nordstrom T; Naslund E; Adolfsson J; Gronberg H
Article: BMC UROLOGY. 2019;19(1):73
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Beckmann K; Kinsella N; Olsson H; Lantz AW; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
Article: BMJ OPEN. 2019;9(6):e027816
Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI
Nordstrom T; Jaderling F; Carlsson S; Aly M; Gronberg H; Eklund M
Journal article: JOURNAL OF RADIATION ONCOLOGY. 2019;8(2):225-231
Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008-2016
Falk J; Aly M; Berglund A; Nordstrom T; Valdman A
Journal article: INVESTIGATIVE UROLOGY. 2019;201(Supplement 4)
MP48-18 IS PSA ‘SCREENING’ BEHAVIOUR ASSOCIATED WITH UPTAKE OF ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER?
Beckmann* K; Kinsella N; Olsen H; Wallerstedt-Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
Article: BMJ OPEN. 2019;9(3):e027958
The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study
Palsdottir T; Nordstrom T; Karlsson A; Gronberg H; Clements M; Eklund M
Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2019;22(1):137-142
The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort
Moller A; Olsson H; Gronberg H; Eklund M; Aly M; Nordstrom T
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2019;18(1):e1532
1132 The effect of common diabetes medications on PSA levels in men without prostate cancer
Jalal NBA; Garmo H; Nordstrom T; Aly M; Eklund M; Aldofsson J; Van Hemelrijck M; Beckmann K
Article: PLOS ONE. 2019;14(6):e0218280
Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
Palsdottir T; Nordstrom T; Aly M; Lindberg J; Clements M; Egevad L; Gronberg H; Eklund M
Article: EUROPEAN UROLOGY. 2018;74(6):722-728
Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging
Gronberg H; Eklund M; Picker W; Aly M; Jaderling F; Adolfsson J; Landquist M; Haug ES; Strom P; Carlsson S; Nordstrom T
Article: GENOME MEDICINE. 2018;10(1):85
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam P-J; Van den Eynden G; Rutten A; Aly M; Nordstrom T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullen A; Yachnin J; Dirix L; Gronberg H; Lindberg J
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1216-1221
Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study
Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2018;17(14):e2898-e2899
P078 Lower Urinary Tract Symptoms (LUTS) not associated to increased risk of prostate cancer
Engel JC; Aly M; Grönberg H; Eklund M; Nordström T
Article: LAKARTIDNINGEN. 2018;115:FCDT
[Improved prostate cancer diagnostics with a struc-tured pathway including the Stockholm3 test and MRI--targeted biopsies - experiences from Capio S:t Göran Prostate Cancer Center].
Bergman M; Hjälm Ericsson M; Jäderling F; Meurling E; Thorstensson A; Nordström T; Henrik G
Article: EUROPEAN UROLOGY FOCUS. 2018;4(5):707-710
The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing
Eklund M; Nordstrom T; Aly M; Adolfsson J; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Presti JC; StLezin M; Clements M; Egevad L; Gronberg H
Article: EUROPEAN UROLOGY. 2018;74(2):204-210
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential
Strom P; Nordstrom T; Aly M; Egevad L; Gronberg H; Eklund M
Article: NATURE GENETICS. 2018;50(7):928-936
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Schumacher FR; Al Olama AA; Berndt SI; Benlloch S; Ahmed M; Saunders EJ; Dadaev T; Leongamornlert D; Anokian E; Cieza-Borrella C; Goh C; Brook MN; Sheng X; Fachal L; Dennis J; Tyrer J; Muir K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman PJ; Thompson IMJ; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger GP; Gronberg H; Aly M; Nordstrom T; Pharoah P; Pashayan N; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Hakansson N; West CML; Dunning AM; Burnet N; Mucci LA; Giovannucci E; Andriole GL; Cussenot O; Cancel-Tassin G; Koutros S; Freeman LEB; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein BS; Kerns SL; Ostrer H; Lu Y-J; Zhang H-W; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; FitzGerald LM; Kibel AS; Drake BF; Vega A; Gomez-Caamano A; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castano-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA; Lin H-Y; Stanford JL; Cybulski C; Wokolorczyk D; Lubinski J; Ostrander EA; Geybels MS; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Roder MA; Iversen P; Brenner H; Cuk K; Holleczek B; Maier C; Luedeke M; Schnoeller T; Kim J; Logothetis CJ; John EM; Teixeira MR; Paulo P; Cardoso M; Neuhausen SL; Steele L; Ding YC; De Ruyck K; De Meerleer G; Ost P; Razack A; Lim J; Teo S-H; Lin DW; Newcomb LF; Lessel D; Gamulin M; Kulis T; Kaneva R; Usmani N; Singhal S; Slavov C; Mitev V; Parliament M; Claessens F; Joniau S; Van den Broeck T; Larkin S; Townsend PA; Aukim-Hastie C; Dominguez MG; Castelao JE; Martinez ME; Roobol MJ; Jenster G; van Schaik RHN; Menegaux F; Truong T; Koudou YA; Xu J; Khaw K-T; Cannon-Albright L; Pandha H; Michael A; Thibodeau SN; McDonnell SK; Schaid DJ; Lindstrom S; Turman C; Ma J; Hunter DJ; Riboli E; Siddiq A; Canzian F; Kolonel LN; Le Marchand L; Hoover RN; Machiela MJ; Cui Z; Kraft P; Conti DV; Easton DF; Wiklund F; Chanock SJ; Henderson BE; Kote-Jarai Z; Haiman CA; Eeles RA
Article: NATURE COMMUNICATIONS. 2018;9(1):2256
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Dadaev T; Saunders EJ; Newcombe PJ; Anokian E; Leongamornlert DA; Brook MN; Cieza-Borrella C; Mijuskovic M; Wakerell S; Al Olama AA; Schumacher FR; Berndt SI; Benlloch S; Ahmed M; Goh C; Sheng X; Zhang Z; Muir K; Govindasami K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman P; Thompson IMJ; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger G; Gronberg H; Aly M; Nordstrom T; Pharoah P; Pashayan N; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Hakansson N; West C; Dunning AM; Burnet N; Mucci L; Giovannucci E; Andriole G; Cussenot O; Cancel-Tassin G; Koutros S; Freeman LEB; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein B; Kerns S; Ostrer H; Lu Y-J; Zhang H-W; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; FitzGerald LM; Kibel AS; Drake BF; Vega A; Gomez-Caamano A; Fachal L; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castano-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA; Lin H-Y; Stanford JL; Cybulski C; Wokolorczyk D; Lubinski J; Ostrander EA; Geybels MS; Nordestgaard BG; Nielsen SF; Weisher M; Bisbjerg R; Roder MA; Iversen P; Brenner H; Cuk K; Holleczek B; Maier C; Luedeke M; Schnoeller T; Kim J; Logothetis CJ; John EM; Teixeira MR; Paulo P; Cardoso M; Neuhausen SL; Steele L; Ding YC; De Ruyck K; De Meerleer G; Ost P; Razack A; Lim J; Teo S-H; Lin DW; Newcomb LF; Lessel D; Gamulin M; Kulis T; Kaneva R; Usmani N; Slavov C; Mitev V; Parliament M; Singhal S; Claessens F; Joniau S; Van den Broeck T; Larkin S; Townsend PA; Aukim-Hastie C; Gago-Dominguez M; Castelao JE; Martinez ME; Roobol MJ; Jenster G; van Schaik RHN; Menegaux F; Truong T; Koudou YA; Xu J; Khaw K-T; Cannon-Albright L; Pandha H; Michael A; Kierzek A; Thibodeau SN; McDonnell SK; Schaid DJ; Lindstrom S; Turman C; Ma J; Hunter DJ; Riboli E; Siddiq A; Canzian F; Kolonel LN; Le Marchand L; Hoover RN; Machiela MJ; Kraft P; Freedman M; Wiklund F; Chanock S; Henderson BE; Easton DF; Haiman CA; Eeles RA; Conti DV; Kote-Jarai Z
Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2018;21(1):57-63
Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
Nordstrom T; Akre O; Aly M; Gronberg H; Eklund M
Article: EUROPEAN UROLOGY FOCUS. 2018;4(3):385-387
Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model
Nordstrom T; Gronberg H; Adolfsson J; Egevad L; Aly M; Eklund M
Article: BMC UROLOGY. 2017;17(1):92
Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy
Nordstrom T; Adolfsson J; Gronberg H; Eklund M
Journal article: CANCER RESEARCH. 2017;77(13_Supplement):1297
Abstract 1297: Genetic reclassification of prostate-specific antigen levels for personalized prostate cancer screening
Graff RE; Hoffmann TJ; Passarelli MN; Emami NC; Sakoda LC; Jorgenson E; Habel LA; Shan J; Ranatunga DK; Quesenberry CP; Chao CR; Ghai NR; Aaronson D; Presti J; Nordström T; Wang Z; Berndt SI; Chanock SJ; Mosley JD; Klein RJ; Middha M; Lilja H; Melander O; Kvale MN; Kwok P-Y; Schaefer C; Risch N; Risch N; Eeden SKVD; Witte JS
Article: WORLD JOURNAL OF UROLOGY. 2017;35(6):895-896
Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Gronberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7
Nordstrom T; Eklund M; Gronberg H
Article: NATURE COMMUNICATIONS. 2017;8:14248
Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer
Hoffmann TJ; Passarelli MN; Graff RE; Emami NC; Sakoda LC; Jorgenson E; Habel LA; Shan J; Ranatunga DK; Quesenberry CP; Chao CR; Ghai NR; Aaronson D; Presti J; Nordstrom T; Wang Z; Berndt SI; Chanock SJ; Mosley JD; Klein RJ; Middha M; Lilja H; Melander O; Kvale MN; Kwok P-Y; Schaefer C; Risch N; Van Den Eeden SK; Witte JS
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2016;108(12):djw165
Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions
Nordstrom T; Adolfsson J; Gronberg H; Eklund M
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):5050
The Stockholm-3 (STHLM3) model to improve prostate cancer testing in men 50-69 years compared to current clinical practice.
Gronberg H; Adolfsson J; Aly M; Nordstrom T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2016;50(2):104-109
A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies
Nordstrom T; Bratt O; Ortegren J; Aly M; Adolfsson J; Gronberg H
Article: PROSTATE. 2016;76(4):339-348
Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer
Nordstroem T; Van Blarigan EL; Ngo V; Roy R; Weinberg V; Song X; Simko J; Carroll PR; Chan JM; Paris PL
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2016;15(3):e86
86 The STHLM3 model improves prostate cancer testing in men 50-69 years - further health economic and clinic evaluation
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2016;15(3):e97
97 Repeat prostate-specific antigen (PSA) tests before biopsy decisions: Results from the STHLM3 diagnostic trial
Nordström T; Adolfsson J; Grönberg H; Eklund M
Article: THE LANCET ONCOLOGY. 2015;16(16):1667-1676
Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study
Gronberg H; Adolfsson J; Aly M; Nordstrom T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Article: EUROPEAN UROLOGY. 2015;68(1):139-146
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer
Nordstrom T; Vickers A; Assel M; Lilja H; Gronberg H; Eklund M
Article: PROSTATE. 2015;75(9):947-956
Rapid Increase in Multidrug-Resistant Enteric Bacilli Blood Stream Infection After Prostate Biopsy-A 10-Year Population-Based Cohort Study
Aly M; Dyrdak R; Nordstrom T; Jalal S; Weibull CE; Giske CG; Gronberg H
Article: EUROPEAN JOURNAL OF CANCER. 2015;51(6):725-733
The risk of prostate cancer for men on aspirin, statin or antidiabetic medications
Nordstrom T; Clements M; Karlsson R; Adolfsson J; Gronberg H
Article: EUROPEAN UROLOGY. 2014;65(6):1184-1190
A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of 1-3 ng/ml
Nordstrom T; Aly M; Eklund M; Egevad L; Gronberg H
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2014;13(1):e860
860 STHLM3 – a prospective diagnostic study of prostate cancer
Gronberg H; Eklund M; Clements M; Nordström T; Aly M; Egevad L; Wiklund F; Brandeberg Y; Wiklund P; Adolfsson J
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2014;13(1):e339
339 A head to head comparison between a 4-kallikrein panel and a [-2]proPSA derivative model
Nordström T; Vickers AJ; Lilja HG; Grönberg H; Eklund M
Article: EUROPEAN UROLOGY. 2013;63(3):419-425
Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003-2011
Nordstrom T; Aly M; Clements MS; Weibull CE; Adolfsson J; Gronberg H
Visa fler

Alla övriga publikationer

Book chapter: CANCER PREVENTION, DETECTION, AND INTERVENTION: LECTURE NOTES IN COMPUTER SCIENCE (INCLUDING SUBSERIES LECTURE NOTES IN ARTIFICIAL INTELLIGENCE AND LECTURE NOTES IN BIOINFORMATICS). 2025;p. 73-82
On Undesired Emergent Behaviors in Compound Prostate Cancer Detection Systems
Sortland Rolfsnes E; Thangngat P; Eftestøl T; Nordström T; Jäderling F; Eklund M; Fernandez-Quilez A
Review: LAKARTIDNINGEN. 2024;121:23192
[Prostate cancer - diagnostics and screening].
Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(4_SUPPL):262
Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.
Vigneswaran HT; Eklund M; Discacciati A; Nordstrom T; Hubbard RA; Perlis N; Abern M; Moreira D; Yonover PM; Chow A; Watts K; Liss MA; Thoreson GR; Abreu AL; Sonn GA; Palsdottir T; Wiklund F; Gronberg H; Murphy AB
Preprint: ARXIV. 2023
Reconsidering evaluation practices in modular systems: On the propagation of errors in MRI prostate cancer detection
Rolfsnes ES; Thangngat P; Eftestøl T; Nordström T; Jäderling F; Eklund M; Fernandez-Quilez A
Preprint: MEDRXIV. 2023
Revisiting prostate segmentation in magnetic resonance imaging (MRI): On model transferability, degradation and PI-RADS adherence
Fernandez-Quilez A; Nordström T; Eftestøl T; Alvestad AB; Jäderling F; Kjosavik SR; Eklund M
Preprint: ARXIV. 2023
Leveraging multi-view data without annotations for prostate MRI segmentation: A contrastive approach
Lindeijer TN; Ytredal TM; Eftestøl T; Nordström T; Jäderling F; Eklund M; Fernandez-Quilez A
Preprint: ARXIV. 2023
Prostate Age Gap (PAG): An MRI surrogate marker of aging for prostate cancer detection
Fernandez-Quilez A; Nordström T; Jäderling F; Kjosavik SR; Eklund M
Letter: JAMA ONCOLOGY. 2023;9(6):868-869
Nonhealing Cutaneous Ulcers in a Patient With Myelodysplastic Syndrome In Reply
Hao S; Nordstrom T; Clements MS
Conference publication: EUROPEAN UROLOGY. 2023;83:S87-S88
Development and multicenter validation of the PROMOD Likert scale including PIRADS score and PSA density for risk stratification of patients with a Positive MRI
Falagario U; Finati M; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G
Conference publication: ANTICANCER RESEARCH. 2023;43(10):4774-4775
ADDITIONAL VALUE OF MAGNETIC RESONANCE IMAGING OF THE PROSTATE IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN >10 NG/ML WITH/WITHOUT POSITIVE DIGITAL RECTAL EXAMINATION: A RETROSPECTIVE MULTICENTER STUDY
Finati M; Guzzi F; Falagario U; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G
Conference publication: ANTICANCER RESEARCH. 2023;43(10):4773-4774
IMPACT OF MAGNETIC RESONANCE IMAGING SCAN AND IMAGE ACQUISITION PROTOCOL IN DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER AT BIOPSY: RESULTS FROM THE PROMOD WORKING GROUP
Finati M; Fanelli A; Falagario U; Lantz A; Jambor I; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Busetto GM; Bettocchi C; Ferro M; Bostrom P; Nordstrom T; De Cobelli O; Cormio L; Carrieri G
Conference publication: EUROPEAN UROLOGY. 2023;83:S379-S380
Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Lantz A; Wiklund P
Corrigendum: EUROPEAN UROLOGY. 2022;82(1):e21
Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study (vol 82, pg 12, 2022)
Hao S; Heintz E; Ostensson E; Discacciati A; Jaderling F; Gronberg H; Eklund M; Nordstrom T; Clements MS
Conference publication: EUROPEAN UROLOGY. 2022;81:S1117-S1118
Diagnosis of prostate cancer in men treated with 5-alpha-reducates inhibitors with multi-parametric MRI: Results of a multicenter international collaboration
Falagario UG; Lantz A; Jambor I; Busetto GM; Carmignani L; Montanari E; Bove P; Gontero P; Sciarra A; Di Tonno P; Trombetta C; Bassi P; Simone G; Mirone V; Antonelli A; Schips L; Bostrom P; Porpiglia F; T N; De Cobelli O; Cormio L; Carrieri G; Ferro M
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2022;170:S360-S361
Derivation and external validation of a RAPID Risk score for predicting significant prostate cancer
Peters M; Eldred-Evans D; Connor MJ; Tanaka MB; Bhola-Stewart H; Shah TT; Ahmad S; Noureldin M; Wong K; Tam H; Hrouda D; Winkler M; van Rossum P; Kurver P; Gordon S; Qazi H; Ahmed HU; Falagario UG; Jambor I; Briganti A; Nordstrom T; Carrieri G; Powell L; Joshi S; Pegers E
Editorial comment: JOURNAL OF UROLOGY. 2022;207(1):231
Re: MRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Eklund M; Jaderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Gronberg H; Nordstrom T
Conference publication: EUROPEAN UROLOGY. 2022;81:S561-S562
Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Conference publication: EUROPEAN UROLOGY. 2022;81:S554-S555
Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies
Bjornebo L; Discacciati A; Eklund M; Gronberg H; Lantz A; Nordstrom T
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2021;385(22):2110-2111
MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
Eklund M; Discacciati A; Nordström T
Preprint: MEDRXIV. 2021
Cost-effectiveness of Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study
Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements M
Corrigendum: NATURE GENETICS. 2021;53(3):413
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (vol 53, pg 65, 2021)
Conti DV; Darst BF; Moss LC; Saunders EJ; Sheng X; Chou A; Schumacher FR; Al Olama AA; Benlloch S; Dadaev T; Brook MN; Sahimi A; Hoffmann TJ; Takahashi A; Matsuda K; Momozawa Y; Fujita M; Muir K; Lophatananon A; Wan P; Le Marchand L; Wilkens LR; Stevens VL; Gapstur SM; Carter BD; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Giles GG; Southey MC; MacInnis RJ; Cybulski C; Wokolorczyk D; Lubinski J; Neal DE; Donovan JL; Hamdy FC; Martin RM; Nordestgaard BG; Nielsen SF; Weischer M; Bojesen SE; Roder MA; Iversen P; Batra J; Chambers S; Moya L; Horvath L; Clements JA; Tilley W; Risbridger GP; Gronberg H; Aly M; Szulkin R; Eklund M; Nordstrom T; Pashayan N; Dunning AM; Ghoussaini M; Travis RC; Key TJ; Riboli E; Park JY; Sellers TA; Lin H-Y; Albanes D; Weinstein SJ; Mucci LA; Giovannucci E; Lindstrom S; Kraft P; Hunter DJ; Penney KL; Turman C; Tangen CM; Goodman PJ; Thompson IMJ; Hamilton RJ; Fleshner NE; Finelli A; Parent M-E; Stanford JL; Ostrander EA; Geybels MS; Koutros S; Freeman LEB; Stampfer M; Wolk A; Hakansson N; Andriole GL; Hoover RN; Machiela MJ; Sorensen KD; Borre M; Blot WJ; Zheng W; Yeboah ED; Mensah JE; Lu Y-J; Zhang H-W; Feng N; Mao X; Wu Y; Zhao S-C; Sun Z; Thibodeau SN; McDonnell SK; Schaid DJ; West CML; Burnet N; Barnett G; Maier C; Schnoeller T; Luedeke M; Kibel AS; Drake BF; Cussenot O; Cancel-Tassin G; Menegaux F; Truong T; Koudou YA; John EM; Grindedal EM; Maehle L; Khaw K-T; Ingles SA; Stern MC; Vega A; Gomez-Caamano A; Fachal L; Rosenstein BS; Kerns SL; Ostrer H; Teixeira MR; Paulo P; Brandao A; Watya S; Lubwama A; Bensen JT; Fontham ETH; Mohler J; Taylor JA; Kogevinas M; Llorca J; Castano-Vinyals G; Cannon-Albright L; Teerlink CC; Huff CD; Strom SS; Multigner L; Blanchet P; Brureau L; Kaneva R; Slavov C; Mitev V; Leach RJ; Weaver B; Brenner H; Cuk K; Holleczek B; Saum K-U; Klein EA; Hsing AW; Kittles RA; Murphy AB; Logothetis CJ; Kim J; Neuhausen SL; Steele L; Ding YC; Isaacs WB; Nemesure B; Hennis AJM; Carpten J; Pandha H; Michael A; De Ruyck K; De Meerleer G; Ost P; Xu J; Razack A; Lim J; Teo S-H; Newcomb LF; Lin DW; Fowke JH; Neslund-Dudas C; Rybicki BA; Gamulin M; Lessel D; Kulis T; Usmani N; Singhal S; Parliament M; Claessens F; Joniau S; Van den Broeck T; Gago-Dominguez M; Castelao JE; Martinez ME; Larkin S; Townsend PA; Aukim-Hastie C; Bush WS; Aldrich MC; Crawford DC; Srivastava S; Cullen JC; Petrovics G; Casey G; Roobol MJ; Jenster G; van Schaik RHN; Hu JJ; Sanderson M; Varma R; McKean-Cowdin R; Torres M; Mancuso N; Berndt SI; Van den Eeden SK; Easton DF; Chanock SJ; Cook MB; Wiklund F; Nakagawa H; Witte JS; Eeles RA; Kote-Jarai Z; Haiman CA
Preprint: SSRN ELECTRONIC JOURNAL. 2021
Prostate Cancer Screening Using a Combination of Risk-Prediction, Magnetic Resonance Imaging and Targeted Prostate Biopsies: A Randomised Trial
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H
Conference publication: EUROPEAN UROLOGY. 2021;79:S1429
Prostate cancer screening using prostate-specific antigen, a multiplex blood-test, magnetic resonance imaging and targeted prostate biopsies: The STHLM3MRI trial
Nordstrom T; Discacciati A; Bergman M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jaderling F; Eklund M; Gronberg H
Conference publication: EUROPEAN UROLOGY. 2021;79:S1430
MRI-targeted or systematic biopsies in prostate cancer screening: The STHLM3MRI trial
Eklund M; Jaderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Gronberg H; Nordstrom T
Letter: BJU INTERNATIONAL. 2020;125(6):763-764
Association between PSA density and prostate cancer in men without significant MRI lesions
Mortezavi A; Eklund M; Bergman M; Kjosavik SR; Discacciati A; Nordstrom T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6)
Incorporating mpMRI and biomarkers in active surveillance protocols: The prospective Stockholm3 Active Surveillance trial (STHLM3AS)
Lantz A; Olsson H; Nordstrom T; Jaderling F; Egevad L; Annerstedt M; Gronberg H; Eklund M
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6)
MRI-targeted biopsies in prostate cancer screening and the value of its combination with blood-based risk-prediction: The randomized, diagnostic study STHLM3MRI
Nordstrom T; Discacciati A; Jaderling F; Karlsson SG; Aly M; Gronberg H; Eklund M
Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2019;111(7):748
RE: Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study Response
Strom P; Lantz AW; Gronberg H; Nordstrom T; Eklund M
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):e16555
Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.
Aly M; Schain F; Leval A; Liwing J; Lawson J; Vago E; Nordstrom T; Gronberg H; Andersson TM-L; Sjoland E; Wang C; Eloranta S; Akre O
Letter: EUROPEAN UROLOGY. 2019;75(4):e104-e105
Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Gronberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol 2018;74:722-8
Eklund M; Strom P; Gronberg H; Nordstrom T
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2019;133:S824-S825
Postoperative radiation therapy following radical prostatectomy in Stockholm County in 2008-2016
Falk J; Aly M; Nordstrom T; Valdman A
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(7):48
The predictive value of DRE in the modern era of prostate cancer diagnostics.
Andersson JM; Nordstrom T; Eklund M; Gronberg H
Corrigendum: NATURE GENETICS. 2019;51(2):363
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (vol 50, pg 928, 2018)
Schumacher FR; Al Olama AA; Berndt SI; Benlloch S; Ahmed M; Saunders EJ; Dadaev T; Leongamornlert D; Anokian E; Cieza-Borrella C; Goh C; Brook MN; Sheng X; Fachal L; Dennis J; Tyrer J; Muir K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman PJ; Thompson IMJ; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger GP; Gronberg H; Aly M; Nordstrom T; Pharoah P; Pashayan N; Schleutker J; Tammela TLJ; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Hakansson N; West CML; Dunning AM; Burnet N; Mucci LA; Giovannucci E; Andriole GL; Cussenot O; Cancel-Tassin G; Koutros S; Freeman LEB; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein BS; Kerns SL; Ostrer H; Lu Y-J; Zhang H-W; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; FitzGerald LM; Kibel AS; Drake BF; Vega A; Gomez-Caamano A; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castano-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA; Lin H-Y; Stanford JL; Cybulski C; Wokolorczyk D; Lubinski J; Ostrander EA; Geybels MS; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Roder MA; Iversen P; Brenner H; Cuk K; Holleczek B; Maier C; Luedeke M; Schnoeller T; Kim J; Logothetis CJ; John EM; Teixeira MR; Paulo P; Cardoso M; Neuhausen SL; Steele L; Ding YC; De Ruyck K; De Meerleer G; Ost P; Razack A; Lim J; Teo S-H; Lin DW; Newcomb LF; Lessel D; Gamulin M; Kulis T; Kaneva R; Usmani N; Singhal S; Slavov C; Mitev V; Parliament M; Claessens F; Joniau S; Van den Broeck T; Larkin S; Townsend PA; Aukim-Hastie C; Gago-Dominguez M; Castelao JE; Martinez ME; Roobol MJ; Jenster G; van Schaik RHN; Menegaux F; Truong T; Koudou YA; Xu J; Khaw K-T; Cannon-Albright L; Pandha H; Michael A; Thibodeau SN; McDonnell SK; Schaid DJ; Lindstrom S; Turman C; Ma J; Hunter DJ; Riboli E; Siddiq A; Canzian F; Kolonel LN; Le Marchand L; Hoover RN; Machiela MJ; Cui Z; Kraft P; Amos CI; Conti DV; Easton DF; Wiklund F; Chanock SJ; Henderson BE; Kote-Jarai Z; Haiman CA; Eeles RA
Corrigendum: NATURE COMMUNICATIONS. 2019;10(1):382
Germline variation at 8q24 and prostate cancer risk in men of European ancestry (vol 9, 4616, 2018)
Matejcic M; Saunders EJ; Dadaev T; Brook MN; Wang K; Sheng X; Al Olama AA; Schumacher FR; Ingles SA; Govindasami K; Benlloch S; Berndt SI; Albanes D; Koutros S; Muir K; Stevens VL; Gapstur SM; Tangen CM; Batra J; Clements J; Gronberg H; Pashayan N; Schleutker J; Wolk A; West C; Mucci L; Kraft P; Cancel-Tassin G; Sorensen KD; Maehle L; Grindedal EM; Strom SS; Neal DE; Hamdy FC; Donovan JL; Travis RC; Hamilton RJ; Rosenstein B; Lu Y-J; Giles GG; Kibel AS; Vega A; Bensen JT; Kogevinas M; Penney KL; Park JY; Stanford JL; Cybulski C; Nordestgaard BG; Brenner H; Maier C; Kim J; Teixeira MR; Neuhausen SL; De Ruyck K; Razack A; Newcomb LF; Lessel D; Kaneva R; Usmani N; Claessens F; Townsend PA; Gago-Dominguez M; Roobol MJ; Menegaux F; Khaw K-T; Cannon-Albright LA; Pandha H; Thibodeau SN; Schaid DJ; Wiklund F; Chanock SJ; Easton DF; Eeles RA; Kote-Jarai Z; Conti DV; Haiman CA; Henderson BE; Stern MC; Thwaites A; Guy M; Whitmore I; Morgan A; Fisher C; Hazel S; Livni N; Cook M; Fachal L; Weinstein S; Freeman LEB; Hoover RN; Machiela MJ; Lophatananon A; Carter BD; Goodman P; Moya L; Srinivasan S; Kedda M-A; Yeadon T; Eckert A; Eklund M; Cavalli-Bjoerkman C; Dunning AM; Sipeky C; Hakansson N; Elliott R; Ranu H; Giovannucci E; Turman C; Hunter DJ; Cussenot O; Orntoft TF; Lane A; Lewis SJ; Davis M; Key TJ; Brown P; Kulkarni GS; Zlotta AR; Fleshner NE; Finelli A; Mao X; Marzec J; MacInnis RJ; Milne R; Hopper JL; Aguado M; Bustamante M; Castano-Vinyals G; Gracia-Lavedan E; Cecchini L; Stampfer M; Ma J; Sellers TA; Geybels MS; Park H; Zachariah B; Kolb S; Wokolorczyk D; Lubinski J; Kluzniak W; Nielsen SF; Weisher M; Cuk K; Vogel W; Luedeke M; Logothetis CJ; Paulo P; Cardoso M; Maia S; Silva MP; Steele L; Ding YC; De Meerleer G; De Langhe S; Thierens H; Lim J; Tan MH; Ong AT; Lin DW; Kachakova D; Mitkova A; Mitev V; Parliament M; Jenster G; Bangma C; Schroder FH; Truong T; Koudou YA; Michael A; Kierzek A; Karlsson A; Broms M; Wu H; Aukim-Hastie C; Tillmans L; Riska S; McDonnell SK; Dearnaley D; Spurdle A; Gardiner R; Hayes V; Butler L; Taylor R; Papargiris M; Saunders P; Kujala P; Talala K; Taari K; Bentzen S; Hicks B; Vogt A; Hutchinson A; Cox A; George A; Toi A; Evans A; van der Kwast TH; Imai T; Saito S; Zhao S-C; Ren G; Zhang Y; Yu Y; Wu Y; Wu J; Zhou B; Pedersen J; Lobato-Busto R; Manuel Ruiz-Dominguez J; Mengual L; Alcaraz A; Pow-Sang J; Herkommer K; Vlahova A; Dikov T; Christova S; Carracedo A; Tretarre B; Rebillard X; Mulot C; Adolfsson J; Stattin P; Johansson J-E; Martin RM; Thompson IMJ; Chambers S; Aitken J; Horvath L; Haynes A-M; Tilley W; Risbridger G; Aly M; Nordstrom T; Pharoah P; Tammela TLJ; Murtola T; Auvinen A; Burnet N; Barnett G; Andriole G; Klim A; Drake BF; Borre M; Kerns S; Ostrer H; Zhang H-W; Cao G; Lin J; Ling J; Li M; Feng N; Li J; He W; Guo X; Sun Z; Wang G; Guo J; Southey MC; FitzGerald LM; Marsden G; Gomez-Caamano A; Carballo A; Peleteiro P; Calvo P; Szulkin R; Llorca J; Dierssen-Sotos T; Gomez-Acebo I; Lin H-Y; Ostrander EA; Bisbjerg R; Klarskov P; Roder MA; Iversen P; Holleczek B; Stegmaier C; Schnoeller T; Bohnert P; John EM; Ost P; Teo S-H; Gamulin M; Kulis T; Kastelan Z; Slavov C; Popov E; Van den Broeck T; Joniau S; Larkin S; Esteban Castelao J; Martinez ME; van Schaik RHN; Xu J; Lindstrom S; Riboli E; Berry C; Siddiq A; Canzian F; Kolonel LN; Le Marchand L; Freedman M; Cenee S; Sanchez M
Conference publication: SCANDINAVIAN JOURNAL OF UROLOGY. 2019;53:40
Improved prostate cancer diagnostics with a structured pathway including the Stockholm3 test and MRI-targeted biopsies led by nurses
Thorstenson A; Melander-Bergstrom C; Cavalli-Bjorkman C; Bergman M; Hjelm-Eriksson M; Jaderling F; Meurling E; Nordstrom T; Gronberg H
Editorial comment: EUROPEAN UROLOGY. 2018;74(6):739-740
Towards Next-generation Urine-based Prostate Cancer Risk Stratification
Nordstrom T; Lindberg J; Eklund M
Letter: EUROPEAN UROLOGY. 2018;74(2):e35-e36
Re: Tobias Nordstrom, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gronberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015; 68: 139-46
Vickers A; Nordstrom T; Assel M; Lilja H; Gronberg H; Eklund M
Letter: EUROPEAN UROLOGY. 2018;74(1):e10-e11
Reply to Ola Bratt and Anna Ofverholm's Letter to the Editor re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.028
Eklund M; Strom P; Nordstrom T; Gronberg H
Preprint: BIORXIV. 2018
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam P-J; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
Editorial comment: EUROPEAN UROLOGY FOCUS. 2017;3(6):526-528
Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project
Nordstrom T; Picker W; Aly M; Jaderling F; Adolfsson J; Strom P; Haug ES; Eklund M; Carlsson S; Gronberg H
Other: UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS. 2017;35(3):120
Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7.
Scott E; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Letter: NATURE REVIEWS CLINICAL ONCOLOGY. 2016;13(6):395-U82
The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments
Eklund M; Gronberg H; Nordstrom T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(2):284
Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) ≥ 7 prostate cancer
Nordstrom T; Adolfsson J; Gronberg H; Eklund M
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(2):36
The risk-based STHLM3 model to improve prostate cancer testing in men 50-69 years: Further health, economic, and clinic evaluation
Gronberg H; Adolfsson J; Aly M; Nordstrom T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Thesis / dissertation: 2015
Predicting prostate cancer : on the use of biomarkers in prostate cancer diagnostics
Nordström, Tobias
Editorial comment: EUROPEAN UROLOGY. 2013;63(3):427
Reply from Authors re: Goutham Vemana, Gerald L. Andriole. Bad Habits May Be Hard to Break. Eur Urol 2013;63:426-7 Changing Habits
Nordstrom T; Clements MS; Adolfsson J; Gronberg H
Visa fler

Anställningar

Anknuten till Forskning, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2024-2026
Anknuten till Forskning, Kliniska vetenskaper, Danderyds sjukhus, Karolinska Institutet, 2022-2025

Examina och utbildning

Docent, urologi, Karolinska Institutet, 2021
Medicine Doktorsexamen, Institutionen för kliniska vetenskaper, Danderyds sjukhus, Karolinska Institutet, 2015
Läkarexamen, Karolinska Institutet, 2005

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI